Antigen News and Research

RSS

Why patients with ALL relapse after CAR-T cell therapy

Researchers have made a new discovery about a rare mechanism that triggers the relapse of acute lymphoblastic leukemia (ALL) after CAR T cell therapy.

1 Oct 2018

Loyola announces plans to produce CAR-T cells for treating cancer

Loyola University Chicago and Loyola Medicine have announced plans to become the first Chicago center to produce cancer-fighting CAR-T cells to treat leukemia and lymphoma.

28 Sep 2018

UCI researchers receive $3.4 million grant to study new class of cancer killing immunotherapeutics

UCI School of Medicine researchers have been awarded a $3.4 million grant by the National Cancer Institute as part of the Beau Biden Cancer Moonshot initiative.

27 Sep 2018

New approach to vaccine development and improved surveillance could help target deadly diseases

Scientists hope that a new approach to vaccine development, combined with improved surveillance of potential future threats of outbreak, could help to massively reduce the impact of deadly diseases such as Ebola, Marburg and Lassa fever.

26 Sep 2018

Overlooked immune cells could play a key role in cancer immunotherapy, claims new study

Cancer immunotherapy is a relatively new method of treating cancer and has succeeded with some refractory tumors. However, it doesn’t always work, why not?

21 Sep 2018

New research finds that MHC-II molecules have more influence on tumors than MHC-I

Cancer immunotherapy -- efforts to boost a patient's own immune system, allowing it to better fight cancer cells on its own -- has shown great promise for some previously intractable cancers.

21 Sep 2018

Innovative approach for developing vaccine against most prevalent human malaria parasite

A novel study indicates promising avenues in an innovative approach for developing a vaccine against Plasmodium vivax, the most prevalent human malaria parasite outside sub-Saharan Africa.

20 Sep 2018

LineaRx signs agreement with Takis/Evvivax to develop linear-DNA based anti-cancer vaccines

Applied DNA Sciences Inc. announced today that LineaRx, Inc., its wholly-owned subsidiary focused on next-generation biotherapeutics, has signed a Joint Development Agreement with Takis S.R.L. and Evvivax S.R.L., biotechnology companies focused on the discovery and development of DNA based anti-cancer vaccines for the human and animal markets, respectively.

20 Sep 2018

Cell Medica successfully doses first patient with CMD-501 targeting pediatric neuroblastoma

Cell Medica announces the treatment of the first patient world-wide to receive CMD-501, an autologous CAR-NKT therapy targeting pediatric neuroblastoma

20 Sep 2018

Surprising research showing peptide adaptability may pave way to develop immunotherapies

The body's immune system is a valiant weapon against disease, and harnessing its power through a technique called immunotherapy is at the forefront of current research to treat cancer and other diseases.

19 Sep 2018

New clinical trial initiated on experimental vaccine to stop the spread of glioblastoma

Rush University Medical Center is part of a new clinical trial testing whether an experimental vaccine can help patients' immune systems stop the spread of glioblastoma -- an aggressive form of brain cancer with veryhttps://www.rush.edu/news/press-releases/rush-testing-new-brain-cancer-vaccine few current treatment options.

14 Sep 2018

Researchers describe mechanism that sets stage for fate decision of T cells

After a pathogen infects the body, the immune system responds with a remarkable -- and remarkably complicated -- cascade of events.

14 Sep 2018

Highly personalized approach may help immune cells to eliminate melanoma

With new immunotherapy treatments for melanoma, recovery rates have risen dramatically, in some cases to around 50%.

12 Sep 2018

Synergism between HOXB13 and CIP2A genes predisposes men to get prostate cancer

A research team at the University of Turku in Finland discovered a link between the interplay of certain simultaneously occurring genetic changes in the HOXB13 and CIP2A genes, aggressiveness of prostate cancer, high risk of developing the disease, and poorer survival rates of patients.

11 Sep 2018

Antigen News and Research

Why patients with ALL relapse after CAR-T cell therapy

Loyola announces plans to produce CAR-T cells for treating cancer

UCI researchers receive $3.4 million grant to study new class of cancer killing immunotherapeutics

New approach to vaccine development and improved surveillance could help target deadly diseases

Overlooked immune cells could play a key role in cancer immunotherapy, claims new study

New research finds that MHC-II molecules have more influence on tumors than MHC-I

Innovative approach for developing vaccine against most prevalent human malaria parasite

LineaRx signs agreement with Takis/Evvivax to develop linear-DNA based anti-cancer vaccines

Cell Medica successfully doses first patient with CMD-501 targeting pediatric neuroblastoma

Surprising research showing peptide adaptability may pave way to develop immunotherapies

New clinical trial initiated on experimental vaccine to stop the spread of glioblastoma

Researchers describe mechanism that sets stage for fate decision of T cells

Highly personalized approach may help immune cells to eliminate melanoma

Synergism between HOXB13 and CIP2A genes predisposes men to get prostate cancer

Major pitfall identified in popular prostate cancer PET imaging method

Groundbreaking CURATE.AI platform halts progression of advanced cancer

NUS researchers harness AI platform to treat patient with advanced cancer

Neurons play active role in triggering a defense mechanism that leads to their own damage

Study shows B cells could play reciprocal roles in pathogenesis of systemic sclerosis

Modified T lymphocytes prevent nerve cell damage in encephalitis

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics